NORWEGIAN BIOTECH AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board: HK
Haakon Korshavn1963
Years since formation: 7 years; since Jan 3, 2017
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 100,000; 1 share class
Total number of shareholders: 1; company
Belongs to group of

Financials

Annual total result 2023: -5,735; NOK
Total equity 2023: -119,988; NOK

Last update: Aug 29, 2024

Management

Board

Name	Role	Shares
SH Siri Helen Torgersen 1964	Board Member	100 % indirectly
HK Haakon Korshavn 1963	Chairman	-

Others

Name	Role	Shares
S SUMMARUM AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
SH Siri Helen Torgersen 1964	Board Member	100 % indirectly

Last update: Apr 13, 2024

Ownership

Company shareholders

Name	Share class	Number of shares	Share
S SKAN HOLDING AS	Ordinary shares	100,000	100 %

Last update: May 24, 2024

Group structure

SKAN HOLDING AS
Total operating income 2023: NOK 179,305
Operating profit 2023: NOK 42,545
Employees: 0

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	0	0	0
Annual Total Result	-5,735	0	-11,756
Total assets	1,838	1,838	1,838
Total liabilities	121,826	116,091	116,091
Total equity	-119,988	-114,253	-114,253

P&L

Year	2023	2021
Total operating income	0	0
Total operating costs	5,735	11,756
Operating result	-5,735	-11,756
Financial income/costs	0	0
Profit before tax	-5,735	-11,756
Total tax & extraordinary income/cost	0	0
Annual Total Result	-5,735	-11,756

Balance overview

Year	2023	2022	2021
Total fixed assets	0	0	0
Total current assets	1,838	1,838	1,838
Total assets	1,838	1,838	1,838
Short term debt	121,826	116,091	116,091
Long term debt	0	0	0
Total liabilities	121,826	116,091	116,091
Contributed capital	30,000	30,000	30,000
Retained earnings	-149,988	-144,253	-144,253
Total equity	-119,988	-114,253	-114,253
Total equity and liabilities	1,838	1,838	1,838

NORWEGIAN BIOTECH AS918 308 377